Medical Devices Alliance

EHRIntelligence | March 11, 2020

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Business Insights

NextRNA Therapeutics | March 02, 2022

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Business Insights

Suvoda LLC | May 13, 2022

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system, and rare disease, today announced they have entered into an agreement to partner with N-SIDE — a deeptech company that empowers organizations in the clinical trials industry to make better decisions and optimize the use of critical resources.  To date, the two companies have successfully partnered on more than 100 clinical ...

Business Insights

CordenPharma | February 01, 2022

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...